| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/07/2009 | CA2699312A1 Compounds for treating abnormal cellular proliferation |
| 05/07/2009 | CA2696237A1 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof |
| 05/07/2009 | CA2695628A1 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors |
| 05/07/2009 | CA2690976A1 Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 05/06/2009 | EP2056111A1 Methods and compositions for regulating protein-protein interactions |
| 05/06/2009 | EP2055784A1 Controlled activation of non-LTR retrotransposons in mammals |
| 05/06/2009 | EP2055711A1 Use of squalenic acid for the formulation of an active principle in nanoparticle state |
| 05/06/2009 | EP2055705A1 Compound having cyclic group bound thereto through spiro binding and use thereof |
| 05/06/2009 | EP2055703A1 Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and pharmaceutical comprising the compound |
| 05/06/2009 | EP2055697A1 Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs |
| 05/06/2009 | EP2055696A1 Acid addition salts of mandelic acid derivatives |
| 05/06/2009 | EP2055313A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 05/06/2009 | EP2055308A1 Pharmaceutical for promoting functional regeneration of damaged tissue |
| 05/06/2009 | EP2055306A1 Application of a gestagen in combination with an oestrogen and one or more pharmaceutically acceptable excipients/media for lactose-free oral contraception |
| 05/06/2009 | EP2055305A1 External preparation comprising prostaglandin derivative |
| 05/06/2009 | EP2055304A1 Stabilized pharmaceutical composition |
| 05/06/2009 | EP2055303A2 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo [5,6] cyclohepta [1,2-b] pyridine oral compositions |
| 05/06/2009 | EP2055302A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 05/06/2009 | EP2055301A1 Solid oral dosage forms comprising valsartan |
| 05/06/2009 | EP2055300A2 Medicament comprising a C11-C21 alkanoic, alkenoic or alkynoic acid ester and a catechin |
| 05/06/2009 | EP2055298A1 Topical composition |
| 05/06/2009 | EP2055297A1 Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature "grayed" patients |
| 05/06/2009 | EP2054529A2 Methods for in vivo identification of endogenous mrna targets of micrornas |
| 05/06/2009 | EP2054504A2 Retinoid compounds and their use |
| 05/06/2009 | EP2054426A1 Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| 05/06/2009 | EP2054425A1 Osmium compounds |
| 05/06/2009 | EP2054424A1 Vinyl phosphonate lysophosphatidic acid receptor antagonists |
| 05/06/2009 | EP2054422A1 Acrylamide derivatives as fab i inhibitors |
| 05/06/2009 | EP2054421A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 05/06/2009 | EP2054420A1 Benzimidazoý1,2-c¨ý1,2,3¨thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof |
| 05/06/2009 | EP2054419A2 Pyrimidinone derivatives and their use as a drug |
| 05/06/2009 | EP2054418A1 Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| 05/06/2009 | EP2054417A2 Fused thiophene derivatives as mek inhibitors |
| 05/06/2009 | EP2054415A1 Adenosine receptor antagonists |
| 05/06/2009 | EP2054414A2 Imidazole amines as inhibitors of beta-secretase |
| 05/06/2009 | EP2054411A1 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| 05/06/2009 | EP2054409A2 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
| 05/06/2009 | EP2054408A2 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level |
| 05/06/2009 | EP2054407A2 Pyrolidine derivatives useful against diseases that depends on activity of renin |
| 05/06/2009 | EP2054406A1 Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy |
| 05/06/2009 | EP2054405A1 Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same |
| 05/06/2009 | EP2054404A1 Imidazole compounds having an antiinflammatory effect |
| 05/06/2009 | EP2054402A1 An aminoisoquinoline thrombin inhibitor with improved bioavailability |
| 05/06/2009 | EP2054401A1 Thiophenecarboxamide derivatives as ep4 receptor ligands |
| 05/06/2009 | EP2054397A1 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 05/06/2009 | EP2054395A2 Piperazine compounds with a herbicidal action |
| 05/06/2009 | EP2054393A1 Crystalline erlotinib |
| 05/06/2009 | EP2054392A2 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
| 05/06/2009 | EP2054390A1 Indazole derivatives that inhibit trpv1 and uses thereof |
| 05/06/2009 | EP2054389A1 6-substituted isoquinoline derivatives as rock-1 inhibitors |
| 05/06/2009 | EP2054388A1 Viral polymerase inhibitors |
| 05/06/2009 | EP2054386A2 Non-flushing niacin analogues, and methods of use thereof |
| 05/06/2009 | EP2054385A2 Phenyl, pyridine and quinoline derivatives |
| 05/06/2009 | EP2054381A2 Pharmacodynamic hybrids endowed of hypoglycemic and no-donor activities obtained combining hydroxylated derivatives of glibenclamide and nitrooxy-substituted carboxylic acids |
| 05/06/2009 | EP2054380A1 Trypsin-like serine protease inhibitors, and their preparation and use |
| 05/06/2009 | EP2054377A1 Chemical compounds |
| 05/06/2009 | EP2054374A1 Novel hydrate form of o-desmethyl venlafaxine succinate |
| 05/06/2009 | EP2054372A2 Crystalline tolterodine tartarate and a pharmaceutical composition containing the same |
| 05/06/2009 | EP2054365A2 Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses |
| 05/06/2009 | EP2054353A2 Methods of maintaining and using a high concentration of dissolved copper on the surface of a useful article |
| 05/06/2009 | EP2054165A2 Method of covering self-assembled metal or inorganic monolayer surfaces of gem-bisphosphonic compounds and uses thereof |
| 05/06/2009 | EP2054084A1 Aerosol formulation for the inhalation of beta agonists |
| 05/06/2009 | EP2054078A2 Long-lasting absorption of flavonoids |
| 05/06/2009 | EP2054076A2 Combination therapy for treatment of viral infections |
| 05/06/2009 | EP2054067A2 Administration of high potency platinum compound formulations by inhalation |
| 05/06/2009 | EP2054066A2 Methods for treatment of radiation enteritis |
| 05/06/2009 | EP2054064A2 Transdermal application of triazines for controlling coccidia infections |
| 05/06/2009 | EP2054063A2 4-aminoquinazoline derivatives and methods of use thereof |
| 05/06/2009 | EP2054062A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 05/06/2009 | EP2054061A2 Combination therapy |
| 05/06/2009 | EP2054060A1 Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| 05/06/2009 | EP2054059A2 Triazole compounds that modulate hsp90 activity |
| 05/06/2009 | EP2054058A2 Inhibitors of pyruvate kinase and methods of treating disease |
| 05/06/2009 | EP2054057A1 Combination andolast/glucocorticoids |
| 05/06/2009 | EP2054056A2 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 05/06/2009 | EP2054055A2 Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
| 05/06/2009 | EP2054054A1 Use of azabicyclo hexane derivatives |
| 05/06/2009 | EP2054051A1 Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis |
| 05/06/2009 | EP2054049A2 Substituted acylanilides and methods of use thereof |
| 05/06/2009 | EP2054048A2 Novel salts of the active substance rasagiline |
| 05/06/2009 | EP2054046A2 Compositions containing chalcones and use thereof |
| 05/06/2009 | EP2054045A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain |
| 05/06/2009 | EP2054044A1 Medicament for lct poisoning |
| 05/06/2009 | EP2054043A2 Nanoparticle compositions |
| 05/06/2009 | EP2054042A1 Methods for the preparation of biologically active compounds in nanoparticulate form |
| 05/06/2009 | EP2054041A2 Formulations of flibanserin and method for manufacturing the same |
| 05/06/2009 | EP2054040A2 Method for making solid dispersions of highly crystalline therapeutic compounds |
| 05/06/2009 | EP2054038A2 Solid dosage form |
| 05/06/2009 | EP2054036A2 Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
| 05/06/2009 | EP2054034A2 Aerosol formulation comprising beta-agonists and steroids |
| 05/06/2009 | EP2054030A1 Antimicrobials |
| 05/06/2009 | EP2053920A1 Inhibition of bacterial biofilms with imidazole derivatives |
| 05/06/2009 | EP2053919A2 Method of reducing neuronal cell damage |
| 05/06/2009 | EP2053918A2 Synthesis of propyl phenoxy ethers and use as delivery agents |
| 05/06/2009 | EP2003211A9 Process for producing optically active (s)-7-hydroxy-6-methylheptane-2-one and precursor thereof |
| 05/06/2009 | EP2002828A9 Solid pharmaceutical preparation |
| 05/06/2009 | EP1973907B1 Imidazo (1,2-a)pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| 05/06/2009 | EP1945635B1 Thiazolyl piperidine derivatives useful as h3 receptor modulators |
| 05/06/2009 | EP1879568B1 Stable pharmaceutical compositions of platinum (ii) antitumour agents |
| 05/06/2009 | EP1865957A4 Method of treating actinic keratosis |